Your source of breaking information about Dutasteride also known as Avodart, Avolve, GI198745, GG745 or Duagen.
dutasteride duagen avodart avolve 
  Dutasteride.org is an independent clearinghouse for information about Dutasteride and is not associated or affiliated with GlaxoSmithKline or the Glaxo Group Limited. Avolve, Avodart and Duagen are registered trademarks of Glaxo Group Limited.  


What is Dutasteride

The Latest News

Dutasteride Studies

Dutasteride Safety Profile

FDA Approval Documents

Dutasteride Results


If you are interested in getting more information via email about the availability of Avodart please enter your email address below

hair loss MPB Dutasteridedutastiride avolve duagen
 
Dutasteride Research Studies
 
Publication: Urology 2002 Sep;60(3):434
Authors: Roehrborn C, Boyle P, Nickel J, Hoefner K, Andriole G.
Institution: Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
 
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
 

Objectives. To study the efficacy and safety of dutasteride, a dual inhibitor of the 5-alpha-reductase isoenzymes types I and II.

Methods. A total of 4325 men (2951 completed) with clinical benign prostatic hyperplasia, moderate to severe symptoms (American Urological Association-Symptom Index score of 12 points or greater), a peak flow rate of 15 mL/s or less, a prostate volume of 30 cm(3) or greater (as measured by transrectal ultrasonography), and a serum prostate-specific antigen level of 1.5 to 10.0 ng/mL (inclusive) were enrolled into three identical clinical trials and randomized to 0.5 mg dutasteride daily or placebo. After a 1-month, single-blind, placebo lead-in, patients were followed up for 24 months in a double-blind trial with multiple interval assessments.

Results. At 24 months, serum dihydrotestosterone was reduced from baseline by a mean of 90.2% (median -93.7%; P <0.001), and the total prostate and transition zone volumes were reduced by a mean of 25.7% and 20.4%, respectively (P <0.001). The symptom score was improved by as early as 3 months, with pooled significance from 6 months onward (P <0.001) and a reduction of 4.5 points (21.4%) at 24 months (P <0.001). The maximal flow rate improved significantly from 1 month (P <0.01), with an increase of 2.2 mL/s reported at 24 months (P <0.001). Hence, the risk reduction of acute urinary retention was 57% and the risk reduction of benign prostatic hyperplasia-related surgical intervention was 48% compared with placebo. The drug was well tolerated.

Conclusions. Dutasteride is a potent inhibitor of dihydrotestosterone production that is safe and effective in terms of the reduction of prostate volume and symptoms, flow rate improvement, and the reduction of the risk of acute urinary retention and surgery during a 24-month study period.

 
lowers DHT and promotes hair regrowth
Glaxo sells Avodart also know as Dutasteride   Avolve Avodart  GI198745  Duagen
 
  Copyright © 2002 Interactive Marketing Group - All Rights Reserved - email: info@dutasteride.org